**Supplementary material: Interview guide**

|  |  |
| --- | --- |
| **Sub-topic** | **Indicative phrasing of questions** |
| Alternative business models for antibiotics/antimicrobials | Internationally alternative models of reimbursement (including delinking reimbursement from sales volumes) have been proposed for antimicrobial drugs. What are your thoughts on the idea that payment for antimicrobial drugs is independent to sales? |
| Do you think a lump-sum reimbursement model for antimicrobials would be possible in Australia?  Globally?  Do you think a lump sum model could work for both high and low-middle income countries? |
| What other incentives do you think may encourage companies to invest in the development of new antimicrobial drugs? |
| Australia has two main funding pathways for medicines in the public sector (Federal funding of medicines on the PBS, and state-funding of drugs used in public hospitals). How do you think that impacts the supply of antimicrobial drugs in Australia?  What is your opinion on states/hospitals tendering for contract prices for antimicrobial drugs? (Price/supply/access) |
| What do you think is the best solution to the challenge of having access to low usage antimicrobials but ensuring companies are appropriately reimbursed? |
|  | What is your opinion regarding a not-for-profit (or government managed) model for antimicrobial supply? |
| Australia’s current regulatory process | A number of antimicrobial drugs are registered overseas but not in Australia. What do you think are the main reasons for this?  What changes (if any) to the regulatory process in Australia do you think would encourage companies to market their products here?  Does your company supply any antimicrobials through the Special Access Scheme? (*for Pharma participants only*) |
|  | What are your thoughts on a possible fast-track approval process for antimicrobial drugs in Australia?  Framework? (similar to EMA PRIME act)  Barriers?  Main concerns (if any)? |
|  | What are your thoughts on regulating antimicrobial drugs differently to other drugs, by possibly establishing a separate schedule of their own? (of the Therapeutic Goods Act) |
|  | What is your opinion on the use of an outcomes registry to gather evidence for new antimicrobials (or to repurpose older drugs)? |
| Do you think the TGA consider pathogen-specific registration instead of indication-specific registration? |
| Has your company withdrawn any antimicrobial products from the Australian market in the last 2-3 years? If so, what was the main reason for the withdrawal? (*for Pharma participants only*) |
| HTA / medicine evaluation / valuing an antimicrobial | How do you think the societal ‘value’ of a new antimicrobial should be determined?  What factors do you think should be considered when assessing the value of a new antimicrobial? |
|  | Antimicrobial resistance to an individual drug is difficult to estimate into the future and is a financial risk for companies investing in antimicrobials drugs. How do you think this risk should be managed or accounted for from a reimbursement perspective? |
| Antimicrobial stewardship | What role, if any, do you believe pharma companies should have with regard to antimicrobial stewardship? |
| Have you heard of the Davos declaration on antibiotic resistance, signed in 2016? (signed by many pharmaceutical companies)   * Do you know if your company is a signatory of the declaration? (*Pharma participants only*) * How binding do you think the declaration is? Do you think there is a risk that companies who haven’t (or even who have) signed, may undermine the efforts of others in conserving antimicrobials? * Why do you think companies may or may not comply with the agreement? |
|  | Do you think reimbursement should be linked in some way to stewardship?  Have you any ideas on how that could work? (i.e. how governments could reward good stewardship)? |
| Sustainable supply | Low usage products have a unique set of challenges in maintaining a supply chain. How do you think the government could assist companies in sustaining supply of antimicrobials?  Shortages - Do you think the government could help with continuity of supply in any way? E.g. assist manufacturing capacity in the case of increased demand |